- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5594
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma ; day:7 ; month:3 ; year:2018 ; pages:1-13
Oncogene ; (7.3.2018), 1-13
- Creator
-
Bolin, Sara
- Contributor
-
Borgenvik, Anna
Persson, Camilla U.
Sundström, Anders
Qi, Jun
Bradner, James E.
Weiss, William A.
Cho, Yoon-Jae
Weishaupt, Holger
Swartling, Fredrik J.
SpringerLink (Online service)
- DOI
-
10.1038/s41388-018-0135-1
- URN
-
urn:nbn:de:1111-201805107998
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bolin, Sara
- Borgenvik, Anna
- Persson, Camilla U.
- Sundström, Anders
- Qi, Jun
- Bradner, James E.
- Weiss, William A.
- Cho, Yoon-Jae
- Weishaupt, Holger
- Swartling, Fredrik J.
- SpringerLink (Online service)
Other Objects (12)
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor